BridgeBio Oncology Therapeutics, Inc. BBOT PHARMA
Company Overview
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -9.50% |
| 6 Months: | -14.06% |
| 3 Months: | +13.88% |
| 1 Month: | -5.04% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)48.45 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 35.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BBOT BridgeBio Oncology Therapeutics, Inc. PHARMA | 8.86 | -3.90 | $710.34M | 0.00% | -35.28% | -81.92% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Income | -66.70K | -152.34K | -19.66M | -23.14M | -1.12M | -49.18M | -46.18M |
| Net Income | -15.44M | -21.82M | -17.32M | -22.05M | -28.43M | -44.76M | -42.11M |
| Diluted EPS | - | - | -1,562.18 | -54.23 | - | -1.03 | -526.11 |
| R&D Expense | - | - | 17.89M | 20.64M | - | 35.05M | 39.80M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Income | -41.69K | -80.86M | -145.82M |
| Net Income | -41.69K | -74.28M | -134.04M |
| Diluted EPS | - | -5,756.41 | -4.30 |
| R&D Expense | - | 73.11M | 121.20M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 5.94M | 164.30M | 448.38M |
| Current Assets | - | 3.94M | 158.69M | 432.40M |
| Cash & Equivalents | - | 250.00K | 30.85M | 373.69M |
| Inventory | - | - | - | - |
| Receivables | - | 1.72M | 81.00K | 386.00K |
| Total Liabilities | - | 121.58M | 342.94M | 37.28M |
| Current Liabilities | - | 16.77M | 19.58M | 35.04M |
| Long Term Debt | - | - | - | - |
| Total Debt | - | - | 0 | 2.77M |
| Total Equity | -21.88K | -115.64M | -178.64M | 411.10M |
| Shares Outstanding | - | 79.20M | 79.20M | 79.99M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -55.03M | -113.89M |
| Investing Cash Flow | -120.53M | 73.33M |
| Financing Cash Flow | 206.29M | 383.40M |
| Capital Expenditure | -49.00K | -606.00K |
| Free Cash Flow | -55.08M | -114.50M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | 0.0% | 41.6% | -32.6% |
| ROCE % | 0.4% | -55.9% | -35.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Cormorant Asset Management, LP | 22.30% | 17.88M | $85.28M |
| 2 | Deerfield Management Company, L.P | 6.09% | 4.89M | $23.30M |
| 3 | Omega Fund Management, Llc | 4.10% | 3.29M | $15.69M |
| 4 | Alphabet Inc. | 3.52% | 2.82M | $13.47M |
| 5 | EcoR1 Capital, LLC | 3.52% | 2.82M | $13.47M |
| 6 | Wellington Management Group, LLP | 3.48% | 2.79M | $13.30M |
| 7 | Enavate Sciences Gp, LLC | 3.28% | 2.63M | $12.53M |
| 8 | Citadel Advisors Llc | 3.27% | 2.62M | $12.49M |
| 9 | Novo Holdings A/S | 2.81% | 2.25M | $10.73M |
| 10 | Blackrock Inc. | 2.69% | 2.15M | $10.27M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BBOT
A cancer drug combination produced responses in 75% of patients at the 500 mg dose - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNS01FTVB5M2VId2NaNHY2WDY2NEItSDNsZXpEUmt3R2ZVVW1WVjNnTkxvY0tUY090RVFNOXlOT0VWT25tZ1RYLXpCOHYzSEozRFoxS1JTcW1fQW5fblljdEJGbXBTTloxZU9wTFZrVjFhQWhCOEtDZktlYW1QQnpOWHVrVWwwTG0zWDRvLT…
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQRlFTYjlzY0hvV1pUX2JWbkpnNHU5NkZmYm9ham9yaFlMWkFnOWpSR3FUWUlZZnJnXzhfSFFzTzJMVThDZUFxTUxyZ3ZtWHMzWWtueTJEMEs0bFl2Q1JEOTlBcVRQbmdrWHAxa3ZzQWtUYWNoM29mdElpTkZpMjNrYTRtLWp6a2lCYTJjNT…
Top BridgeBio Oncology Therapeutics (BBOT) Competitors 2026 - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxOTEdyRVJIeWRzdUxRTzgxb29IQ0N1TVdyb256ME5iMDVfbnNnWF9DTWVMWFFGbkNkQzU2dDFaQTlyMmRORVJUTVVDUV90emFFZmRlNzNWWk8tb1o1ZW1ESW1uV0xCZjhIUHdUWkZXYnRPUnZXT01TTFBSMjhLcks1cw?oc=5" target="_…
BBOT shakes up leadership as RAS competitors get more visibility - BioSpace
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNckNZQTVUOC1lc0tGZTNHMEFqdzFfVlU2RURwdGwxQm9kc0J3azZudVRCcEpyX0gyTXByWW53aEZHeDJaSzRMUGJseHgyaWN6TXVSUDRiUVFBVnA1YjhmcmxOaWt2NExHeWRvNlcxQnNzNFp0RW84T1FhMl8tME1hZUU1YTdGdmhpVTk2en…
BBOT Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBLTVJLTnctN21JaUZYd0NoMWhMdzI0Z2RkellDbmVWUVVXMTg2MU1jbkJveUQ5dktoaEl0MC05bmFXLVl0RGRnNjd2ZlZKN2p4aHZaV1lBY3VFUFZ0Z1o3UjVsQlJPcTZjVUhhRmx3SXNrQjdrMGtQREx3?oc=5" target="_blank">BBO…
BBOT - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1yQ3ZSbUlodFF0Q2d3ZDZub2NJamQ0UTF2cnlXcldpVXI2cWNPckFsUGM2UEJuQ0RyZi1EU3JwcG5wanhpdnc?oc=5" target="_blank">BBOT</a> <font color="#6f6f6f">Finviz</font>…
BBOT — Frequently Asked Questions
What is the current share price of BridgeBio Oncology Therapeutics, Inc. (BBOT)?
As of 2026-09-19 21:16 PDT, BridgeBio Oncology Therapeutics, Inc. (BBOT) trades at $8.86 on NasdaqGM. Its 52-week range is $7.12 to $13.73.
What is the market capitalisation of BBOT?
BridgeBio Oncology Therapeutics, Inc. (BBOT) has a market capitalisation of $710.34M on NasdaqGM.
What is the P/E ratio of BBOT?
BBOT trades at a trailing price-to-earnings (P/E) ratio of -3.90. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.67.
What is the return on equity (ROE) of BBOT?
BBOT has a return on equity (ROE) of -81.92%. Its return on capital employed (ROCE) is -35.28%.
Is BBOT a good stock to buy?
This page provides a data-driven analysis of BridgeBio Oncology Therapeutics, Inc. (BBOT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.